Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors

Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors

US Patent 11439620 · Granted Sep 13, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Systems and methods for hemoclip deployment2025
Tool for hemostasis and tissue approximation2025
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2025
Antibody-drug conjugates and uses thereof2025
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2025
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2023
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PAR2022
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PAR2022
Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors rel2021
Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malign2021
Immunoconjugates with an intracellularly-cleavable linkage2021
Antibody-drug conjugates and uses thereof2021